Comorbilidades y su manejo en portadores de EPOC

2. COPD and Multimorbidity
Recognizing and Addressing a Syndemic Occurrence?

3. Clusters of Common Morbidities
Frequently Present in COPD

4. Using a Proactive Complementary Approach to
Detect Comorbidities in All Patients With COPD

5. Comorbidities in COPD Are Often
Underdiagnosed

6. Definition of COPD-Multimorbidity
Syndemics

7. Syndemic Prototypes: COPD, Diabetes,
and CVD

8. Exacerbations Drive COPD Outcomes

9. Comorbid Conditions May Mimic or Worsen COPD
Exacerbations and Require Careful Evaluation[1,2]

10. Differential Diagnosis of Suspected
COPD Exacerbations in the Acute Care
Setting

11. Precise Diagnosis Allows Effective Management
of Both COPD Exacerbations and Comorbidities

12. Intensified Diagnostics and Multimorbidity Evaluation
Are Recommended During Worsening Episodes

13. Managing COPD With Multimorbidity
Requires a Person-Centered Approach

14. Conclusions

16. What Are COPD Exacerbations?

17. COPD In-Hospital Mortality

18. Comorbidities During and After COPD
Exacerbations

19. The COPD Spiral of Decline After
Exacerbation

20. What Happens During an
Exacerbation?

21. Comorbidities Lead to Increased
Patient Needs in COPD

22. Comorbidities Lead to Increased
Patient Needs in COPD

23. Managing Comorbidities Following a COPD
Exacerbation
GOLD Discharge Criteria and Follow-Up Recommendations

24. Managing Comorbidities Following a COPD
Exacerbation
GOLD Discharge Criteria and Follow-Up Recommendations (cont)

25. Interventions That Reduce COPD Exacerbation
Frequency
GOLD Recommendations

26. Interventions That Reduce COPD Exacerbation
Frequency
GOLD Recommendations

27. Interventions That Reduce COPD Exacerbation
Frequency
GOLD Recommendations

28. Interventions That Reduce COPD Exacerbation
Frequency
GOLD Recommendations

29. Interventions That Reduce COPD Exacerbation
Frequency
GOLD Recommendations

30. Interventions That Reduce COPD Exacerbation
Frequency
GOLD Recommendations

31. Evidence Supporting Reduction in Mortality With
Pharmacotherapy and Nonpharmacotherapy in Patients With
COPD

32. Key Takeaways

34. Case Study
History

35. Case Study
Examinations and Tests at Admission

36. Case Study
Diagnosis and Initial Treatment

37. Case Study
Treatment Adjustment (cont)

38. Case Study
Treatment Adjustment (cont)

39. Case Study
Follow-Up 2 Weeks After Discharge

40. Case Study
Follow-Up 2 Weeks After Discharge

41. Assessments Required for Diagnosis
and Differential Diagnosis in This
Patient

42. Assessments Required for Diagnosis
and Differential Diagnosis in This
Patient

43. Assessments Required for Diagnosis
and Differential Diagnosis in This
Patient

44. Assessments Required for Diagnosis
and Differential Diagnosis in This
Patient

45. Assessments Required for Diagnosis
and Differential Diagnosis in This
Patient

46. How to Triage the Patient for Early
Intervention
and Prevention

47. Asthma and COPD May Coexist
What Drives It and How We Treat It

48. Key Takeaways

50. Patient Case

51. Mechanisms Linking COPD and T2DM

52. Major CV Risks Elevated in Patients With COPD and
T2DM

53. Management of T2DM in Patients With Multimorbid
COPD

54. Pharmacological Considerations in
Comorbid COPD and T2DM

55. Pharmacological Considerations in
Comorbid COPD and T2DM

56. Pleiotropic Effects of Incretins, Gliptins,
and Glifozins

57. 2023 AACE Algorithms for Managing
Prediabetes and Diabetes
Complications

58. Conclusions

60. Patient Case

61. Patient Case (cont)

62. Patient Case (cont)

63. Anxiety and Depression Are Frequent,
Yet Underdiagnosed, Comorbidities in
COPD

64. Untreated, These Psychiatric
Conditions May Lead to Other Issues

65. Key Clinical Considerations
The GOLD Strategy Report

66. Screening Tools

67. Management

68. Pulmonary Rehabilitation, Self-Management, and
Integrative Care Are Important Parts of Managing COPD

69. COPD Follow-Up Checklist